RYVYL and Roundtable Announce Public Filing of Registration Statement on Form S-4 and Proxy Statement/Prospectus in Connection with Proposed Merger

Stock Information for Ventyx Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Ventyx Biosciences Inc.

SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--VTYX, ALEX, RVYL, and FFWM
RYVYL ANNOUNCES NASDAQ COMPLIANCE AHEAD OF ANTICIPATED MERGER WITH ROUNDTABLE; S-4 FILED
RYVYL Highlights Recent Developments for Merger Partner Roundtable that Advance Web3 Platform Traction
RYVYL Announces 1-for-35 Reverse Stock Split of Common Stock
RYVYL Announces Stockholder Approval of Annual Meeting Proposals; Reverse Stock Split Process Commences to Remedy Nasdaq Delisting Notice
Court Provisionally Approves Settlement of RYVYL Derivative Litigation
Roundtable CEO James Heckman to Host Virtual Investor Event on Thursday, November 20 Ahead of Merger with RYVYL
Roundtable CEO James Heckman Announces New CFO, Aly Madhavji, Visionary Investor and Blockchain Founders Fund Managing Partner, To Lead RYVYL Merger, NASDAQ Listing

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.